About E3 ubiquitin-protein ligase Hakai
E3 ubiquitin-protein ligase Hakai (CBLL1) is a protein
from Homo sapiens identified by UniProt accession
Q75N03, 491 residues long.
MolForge cross-references it against 0 known binders and
75 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase Hakai |
| UniProt accession | Q75N03 |
| Gene | CBLL1 |
| Organism | Homo sapiens |
| Length | 491 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (75)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.55
- listeriosis · score 0.46
- lysosomal storage disease · score 0.37
- lymphocyte count · score 0.28
- endometrial cancer · score 0.23
- hepatocellular carcinoma · score 0.20
- clear cell renal carcinoma · score 0.17
- gastric adenocarcinoma · score 0.11
- neoplasm · score 0.10
- non-small cell lung carcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q75N03-F1 | alphafold | PREDICTED | 56.60 | — |
Amino-acid sequence (491 residues)
MDHTDNELQG TNSSGSLGGL DVRRRIPIKL ISKQANKAKP APRTQRTINR MPAKAPPGDE EGFDYNEEER YDCKGGELFA NQRRFPGHLF WDFQINILGE KDDTPVHFCD KCGLPIKIYG RMIPCKHVFC YDCAILHEKK GDKMCPGCSD PVQRIEQCTR GSLFMCSIVQ GCKRTYLSQR DLQAHINHRH MRAGKPVTRA SLENVHPPIA PPPTEIPERF IMPPDKHHMS HIPPKQHIMM PPPPLQHVPH EHYNQPHEDI RAPPAELSMA PPPPRSVSQE TFRISTRKHS NLITVPIQDD SNSGAREPPP PAPAPAHHHP EYQGQPVVSH PHHIMPPQQH YAPPPPPPPP ISHPMPHPPQ AAGTPHLVYS QAPPPPMTSA PPPITPPPGH IIAQMPPYMN HPPPGPPPPQ HGGPPVTAPP PHHYNPNSLP QFTEDQGTLS PPFTQPGGMS PGIWPAPRGP PPPPRLQGPP SQTPLPGPHH PDQTRYRPYY Q
Explore E3 ubiquitin-protein ligase Hakai with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets